Veristat, Inc. And Karyopharm Therapeutics (KPTI) Enter Into Preferred Provider Agreement For Oncology And Novel Therapeutic Advancement
6/16/2014 10:27:53 AM
HOLLISTON, Mass.--(BUSINESS WIRE)--Veristat, a full service Contract Research Organization, announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a Preferred Provider agreement with Veristat.
Help employers find you! Check out all the jobs and post your resume.
comments powered by